Corvus Pharmaceuticals
CRVS
52 hedge funds and large institutions have $212M invested in Corvus Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 13 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
0.77% more ownership
Funds ownership: 82.82% → 83.59% (+0.77%)
0% more funds holding
Funds holding: 52 → 52 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
41% less capital invested
Capital invested by funds: $360M → $212M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.59M |
| 2 |
Jennison Associates
New York
|
+$5.07M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.93M |
| 4 |
BlackRock
New York
|
+$2.03M |
| 5 |
JP Morgan Chase
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.81M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$2.79M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$2.53M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.88M |
CRVS Hedge Fund Activity: Q2 2017 in Review
52 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2017, worth a combined $212M — down 41% from $360M a quarter earlier.
Fund positioning in CRVS was balanced in Q2 2017: 13 funds opened new positions, 13 closed out, 22 added to existing stakes and 10 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.59M. The largest seller was Fidelity Investments, cutting an estimated $11.4M.
- 52 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $212M of Corvus Pharmaceuticals stock for Q2 2017, down 41% quarter-over-quarter.
- 13 funds opened new Corvus Pharmaceuticals positions in Q2 2017 and 13 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2017 was EcoR1 Capital, an estimated $8.59M added.
- The largest Corvus Pharmaceuticals seller in Q2 2017 was Fidelity Investments, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2017.